OFANIB 5 mg: Each film-coated tablet contains Tofacitinib citrate INN 8.0 mg equivalent to Tofacitinib 5 mg.
TOFANIB 11 mg XR: Each extended release tablet contains Tofacitinib citrate INN 17.77 mg equivalent to Tofacitinib 11 mg.
Tofanib is the citrate salt of Tofacitinib, an inhibitor of Janus Kinase (JAK). JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Tofacitinib modulates the signaling pathway of cytokine at the point of JAKs, preventing the phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. The absolute oral bioavailability of Tofacitinib is 74%. The metabolism of Tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19.